PB 25 of 2024
National Health (April 2024 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2024
National Health Act 1953
I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged, delegate of the Minister for Health and Aged Care make this determination under subsection 99ACC(5C) and subsection 99ACF(3) of the National Health Act 1953.
Dated 28 February 2024
NIKOLAI TSYGANOV
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Health Resourcing Group
Department of Health and Aged Care
(1) This instrument is the National Health (April 2024 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2024.
(2) This instrument may also be cited as PB 25 of 2024.
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information |
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | The day this instrument is registered. | |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
Note: A number of expressions used in this instrument are defined in Part VII the Act.
In this instrument:
Act means the National Health Act 1953.
reduction day in this instrument refers to 1 April 2024.
This instrument is made under subsection 99ACC(5C) and subsection 99ACF(3) of the Act.
5 Brand of pharmaceutical item (combination item) not subject to a price reduction
I determine, under paragraph 99ACC(5C)(a) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each single brand of combination item specified in column 2 as an item in the table in Schedule 1 is not reduced under subsection 99ACC(2) or subsection 99ACC(5) of the Act, as appropriate, in relation to the reduction day.
6 Brand of pharmaceutical item not subject to a price reduction
I determine, under paragraph 99ACF(3)(a) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 2 is not reduced under a provision mentioned in item 2A or item 3A or item 4A or item 8 of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the reduction day.
7 Brand of pharmaceutical item subject to a lower price reduction than would otherwise apply
I determine, under paragraph 99ACF(3)(b) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of a brand of pharmaceutical item specified in column 2 of an item in the table in Schedule 3 is reduced under a provision mentioned in item 4A of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the reduction day by the percentage specified in column 3 of the table item.
Schedule 1 — Brands of pharmaceutical items (combination items) with approved ex-manufacturer price not reduced
Column 1 | Column 2 |
Item | Brand of Combination Item |
| Drug | Form | Manner of administration | Brand(s) |
1 | Beclometasone with formoterol and glycopyrronium | Pressurised inhalation containing beclometasone dipropionate 200 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses | Inhalation by Mouth | Trimbow |
2 | Beclometasone with formoterol and glycopyrronium | Pressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses | Inhalation by Mouth | Trimbow |
Schedule 2— Brands of pharmaceutical items with approved ex-manufacturer price not reduced
Column 1 | Column 2 |
Item | Brand of Pharmaceutical Item |
| Drug | Form | Manner of administration | Brand(s) |
1 | Amylopectin, modified long chain | Sachets containing oral powder 60 g, 30 (Glycosade) | Oral | Glycosade |
2 | Essential amino acids formula with vitamins and minerals | Sachets containing oral powder 12.5 g, 30 (EAA Supplement) | Oral | EAA Supplement |
3 | Glycomacropeptide and essential amino acids with vitamins and minerals | Bars 81 g, 7 (Camino Pro Complete) | Oral | Camino Pro Complete |
4 | Glycomacropeptide and essential amino acids with vitamins and minerals | Oral liquid 250 mL, 30 (PKU Glytactin RTD 15 Lite) | Oral | PKU Glytactin RTD 15 Lite |
5 | Glycomacropeptide and essential amino acids with vitamins and minerals | Oral liquid 250 mL, 30 (PKU Glytactin RTD 15) | Oral | PKU Glytactin RTD 15 |
6 | Glycomacropeptide and essential amino acids with vitamins and minerals | Sachets containing oral powder 16 g, 60 (PKU Build 10) | Oral | PKU Build 10 |
7 | Glycomacropeptide and essential amino acids with vitamins and minerals | Sachets containing oral powder 32 g, 30 (PKU Build 20) | Oral | PKU Build 20 |
8 | Glycomacropeptide and essential amino acids with vitamins and minerals | Sachets containing oral powder 20 g, 60 (PKU Restore) | Oral | PKU Restore |
9 | Glycomacropeptide and essential amino acids with vitamins and minerals | Sachets containing oral powder 40 g, 30 (Camino Pro Bettermilk) | Oral | Camino Pro Bettermilk |
10 | Nicotine | Transdermal patch 114 mg | Transdermal | Nicabate P |
11 | Nicotine | Transdermal patch 17.5 mg | Transdermal | Nicotinell Step 3 |
12 | Nicotine | Transdermal patch 35 mg | Transdermal | Nicotinell Step 2 |
13 | Nicotine | Transdermal patch 39.4 mg | Transdermal | nicorette 16hr Invisipatch |
14 | Nicotine | Transdermal patch 52.5 mg | Transdermal | Nicotinell Step 1 |
15 | Phenylalanine with carbohydrate | Sachets of oral powder 4 g containing 50 mg phenylalanine, 30 (Phenylalanine 50) | Oral | Phenylalanine 50 |
16 | Tyrosine with carbohydrate | Sachets of oral powder 4 g containing 1 g tyrosine, 30 (Tyrosine 1000) | Oral | Tyrosine 1000 |
17 | Whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose | Oral powder 400 g, 6 (Renastart) | Oral | Renastart |
Schedule 3 — Brands of pharmaceutical items with approved ex-manufacturer price reduced by a lower percentage than would otherwise apply
Column 1 | Column 2 | Column 3 |
Item | Brand of pharmaceutical item | % reduction |
| Drug | Form | Manner of administration | Brand | |
1 | Triptorelin | Powder for I.M. injection (prolonged release) 22.5 mg (as embonate) with solvent, syringe and needles | Injection | Diphereline | 25.17% |